Engineered immune cells take on tough lymphoma
NCT ID NCT07473167
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called TC011, which uses a patient's own immune cells engineered to find and attack lymphoma cells. It is for adults with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The trial will check safety and how well the therapy works in 98 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TC011 (a type of CAR-T cell therapy that targets CD19 on cancer cells)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat large B-cell lymphoma that has not responded to standard chemotherapy.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 98 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and nervous system problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul, 03080, South Korea
Contact